Physician profile
Scott E Rinesmith
NPI 1790837433
$12,947.33
in general payments reported to CMS, 2019-2025
47 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $585 · 2021: $1,362 · 2022: $1,816 · 2023: $2,334 · 2024: $2,982 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,680 · Education: $89.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,679.90 |
| Education | $89.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,165.13 | 2019-2025 | Rinvoq, Linzess, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $2,061.58 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,762.38 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $807.83 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $474.80 | 2019-2025 | Livdelzi |
| Qol Medical, LLC | $444.96 | 2020-2025 | Sucraid, Sucraid |
| Pfizer INC. | $368.19 | 2019-2025 | |
| Ardelyx, INC. | $294.09 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $283.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $275.67 | 2020-2024 | Dificid |
| Daiichi Sankyo INC. | $275.46 | 2019-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $238.88 | 2019-2025 | Rebyota |
| Genzyme Corporation | $224.94 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $219.90 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $207.33 | 2020-2024 | Linzess |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $181.82 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $155.93 | 2020-2023 | |
| Amgen INC. | $149.80 | 2025 | Uplizna |
| Davol INC. | $136.10 | 2024 | Phasix Mesh |
| Ipsen Biopharmaceuticals, INC | $126.17 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $113.21 | 2024-2025 | Omvoh |
| Organon LLC | $98.42 | 2021-2025 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $96.91 | 2019-2023 | Sutab |
| Lucid Diagnostics INC. | $91.33 | 2021-2025 | |
| Celltrion USA INC. | $77.26 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Boston Scientific Corporation | $71.71 | 2019 | |
| Madrigal Pharmaceuticals | $60.26 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $58.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.80 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $47.52 | 2022-2024 | Gimoti |
| Shionogi INC | $39.87 | 2019 | |
| Aimmune Therapeutics, INC. | $29.25 | 2024-2025 | Vowst |
| Allergan, INC. | $26.87 | 2019 | |
| Redhill Biopharma INC. | $26.06 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $25.57 | 2019-2021 | |
| Abbott Laboratories | $23.49 | 2023 | Mitraclip |
| Pacira Pharmaceuticals Incorporated | $18.75 | 2022 | |
| Biocon Biologics INC | $18.08 | 2025 | Yesintek |
| Sandoz INC. | $15.63 | 2024 | Hyrimoz |
| Ucb, INC. | $15.56 | 2019 | |
| Fresenius Kabi USA, LLC | $15.31 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $14.73 | 2021 | |
| Shire North American Group INC | $13.82 | 2019 | |
| Romark Laboratories, Lc | $13.51 | 2020 | |
| Medtronic, INC. | $13.11 | 2021 | |
| Alfasigma USA, INC. | $11.03 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rinesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.